- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00003945
Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for cervical cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of three different chemotherapy regimens in treating patients with stage IVB, recurrent, or persistent cervical cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Compare the response rate and survival of patients with stage IVB, recurrent, or persistent carcinoma of the cervix treated with cisplatin only vs cisplatin plus topotecan vs methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). (Arm III (MVAC) closed to accrual effective 07/23/2001.)
- Compare the toxic effects of these regimens in this patient population.
- Compare health-related quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to GOG performance status. Patients are randomized to one of three treatment arms. (Arm III closed to accrual effective 07/23/2001.)
- Arm I: Patients receive cisplatin IV once every 21 days.
- Arm II:Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin IV (beginning after topotecan infusion) on day 1. Courses repeat every 21 days.
- Arm III:Patients receive methotrexate IV on days 1, 15, and 22, vinblastine IV on days 2, 15, and 22, and doxorubicin IV and cisplatin IV on day 2. Courses repeat every 28 days. (Arm III closed to accrual effective 07/23/2001.) Treatment in all arms continues for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. (Arm III closed to accrual effective 07/23/2001.)
Quality of life is assessed before randomization, before course 2, before course 5 (arms I and II), before course 4 (arm III), and at 9 months. (Arm III closed to accrual effective 07/23/2001.)
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 400 patients (133 per treatment arm) will be accrued for this study within 2 years. (Arm III closed to accrual effective 07/23/2001.)
Type d'étude
Inscription (Anticipé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Westmead, New South Wales, Australie, 2145
- Westmead Hospital
-
-
-
-
-
San Juan, Porto Rico, 00936-7344
- San Juan City Hospital
-
-
-
-
-
Lima, Pérou, 34
- Instituto De Enfermedades Neoplasicas
-
-
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202-5289
- Indiana University Cancer Center
-
-
Iowa
-
Des Moines, Iowa, États-Unis, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, États-Unis, 50316-2301
- Iowa Lutheran Hospital
-
Des Moines, Iowa, États-Unis, 50314
- Mercy Cancer Center at Mercy Medical Center-Des Moines
-
-
Nebraska
-
Papillion, Nebraska, États-Unis, 68128-4157
- Midlands Cancer Center at Midlands Community Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87131
- MBCCOP - University of New Mexico HSC
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, États-Unis, 54307-3453
- CCOP - St. Vincent Hospital Cancer Center, Green Bay
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically confirmed stage IVB, recurrent, or persistent carcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiotherapy
Eligible subtypes:
- Squamous cell carcinoma
- Adenosquamous carcinoma
- Adenocarcinoma
Measurable disease by physical examination, radiography, CT scan, or MRI
- Measurable disease by CT scan/MRI without biopsy confirmation allowed if lesions are at least 3 cm and well defined
- No craniospinal metastases
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- GOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times normal
- SGOT no greater than 3 times normal
- Alkaline phosphatase no greater than 3 times normal
Renal:
- Creatinine no greater than 1.5 mg/dL
- No bilateral hydronephrosis that cannot be alleviated by ureteral stents or percutaneous drainage
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No clinically significant infection
- No other prior invasive malignancy within the past 5 years except nonmelanoma skin cancer
- Body surface area no greater than 2.0 m^2
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- At least 6 weeks since prior chemoradiotherapy and recovered
- No prior chemotherapy except when used concurrently with radiotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
- See Chemotherapy
- At least 3 weeks since prior radiotherapy only and recovered
Surgery:
- Recovered from prior surgery
Other:
- No prior anticancer treatment that would preclude study therapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Higinia R. Cardenes, MD, PhD, Indiana University Melvin and Bren Simon Cancer Center
Publications et liens utiles
Publications générales
- Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH, Monk BJ. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May;125(2):315-9. doi: 10.1016/j.ygyno.2012.01.047. Epub 2012 Feb 1.
- Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Jan;116(1):44-9. doi: 10.1016/j.ygyno.2009.09.006. Epub 2009 Oct 22.
- Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, Eastwood A. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health Technol Assess. 2010 May;14 Suppl 1:55-62. doi: 10.3310/hta14Suppl1/08.
- Plaxe SC, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol. 2008 Nov;199(5):539.e1-6. doi: 10.1016/j.ajog.2008.04.038. Epub 2008 Jun 20.
- Moore DH, Tian C, Monk BJ, et al.: Factors predictive of response to cisplatin-based chemotherapy in stage IVB persistent or recurrent cervical carcinoma: a multivariate analysis of three Gynecologic Oncology Group trials. [Abstract] J Clin Oncol 25 (Suppl 18): A-5534, 282s, 2007.
- Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005 Nov;7(6):419-34. doi: 10.1007/s11912-005-0007-z.
- Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar;100(3):537-43. doi: 10.1016/j.ygyno.2005.09.023. Epub 2005 Oct 10.
- Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33. doi: 10.1200/JCO.2005.10.021. Epub 2005 May 23.
- Monk BJ, Huang HQ, Cella D, Long HJ 3rd; Gynecologic Oncology Group Study. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4617-25. doi: 10.1200/JCO.2005.10.522. Epub 2005 May 23. Erratum In: J Clin Oncol. 2005 Nov 20;23(33):8549.
- Grendys EC Jr, Long HJ, Bundy BN, et al.: Randomized phase III trial of cisplatin vs cisplatin plus topotecan vs the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group study. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-039, 12, 2004.
- Monk BJ, Huang H, Cella D, et al.: Quality of life outcomes from GOG 179: a phase III trial of cisplatin vs cisplatin/topotecan in recurrent or persistent carcinoma of the cervix. [Abstract] Int J Gynecol Cancer 14 (Suppl 1): A-142, 42, 2004.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs utérines
- Tumeurs génitales, femme
- Maladies du col de l'utérus
- Maladies utérines
- Tumeurs du col de l'utérus
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de la topoisomérase
- Inhibiteurs de la topoisomérase I
- Topotécan
Autres numéros d'identification d'étude
- CDR0000067138
- GOG-0179
- ECOG-G0179
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du col de l'utérus
-
Imperial College Healthcare NHS TrustImperial College London; The Wellington Hospital, LondonComplété
-
Duke UniversityNational Cancer Institute (NCI); Jacobi Medical CenterComplété
-
Michigan State UniversityAmerican Osteopathic AssociationComplété
-
Duke UniversityUniversity of ArkansasComplété
-
New York Institute of TechnologyComplété
-
Michigan State UniversityComplété
-
NuVasiveActif, ne recrute pasTrouble discal dégénératif cervicalÉtats-Unis
-
Goethe UniversityComplétéCinématique | Fiabilité | CervicalAllemagne
-
Xin Jiang, MDInconnueBloc du plexus cervical superficielChine
-
National Cancer Institute (NCI)ComplétéPoumon | Sein | Ovaire | Cervical | RénalÉtats-Unis